Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
13 pending office actions • 7 art units • 11 examiners • 0 of 13 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Seagen Inc. is currently navigating 13 pending office actions within the Biotechnology & Pharmaceuticals technology area. This significant volume of active matters is spread across 11 distinct examiners and 7 distinct art units. Such a broad distribution suggests a complex prosecution landscape where strategies must be tailored to a wide variety of examiner preferences and art unit norms. With 7 distinct art units involved, Seagen Inc. demonstrates a wide reach within the sector.
The busiest examiner for this portfolio is PUTTLITZ, KARL J, who is currently managing 2 pending office actions. While this examiner handles more matters than others, the 2 actions represent a relatively small fraction of the 13 pending office actions total. This indicates that the portfolio is not overly dependent on the decisions of a single individual, despite the high total count of 11 distinct examiners. Managing 13 pending office actions across 11 distinct examiners requires coordination to ensure consistency. The workload of 2 actions for PUTTLITZ, KARL J serves as a focal point in an otherwise decentralized set of matters.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (23%) |
| §102 only | 1 (8%) |
| Double-patenting only | 2 (15%) |
| Double-patenting + other | 4 (31%) |
| Multi-statute (no §101) | 3 (23%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PUTTLITZ, KARL J | 2 | 69.1% | +18.6% |
| ALSOMAIRY, SARAH ABDOALATIF | 2 | 57.8% | +30.2% |
| PETRASH, HILARY ANN | 1 | 64.5% | +51.7% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.2% |
| SHAMEEM, GOLAM M | 1 | 86.7% | +16.0% |
| BENAVIDES, JENNIFER ANN | 1 | 51.2% | +47.0% |
| LU, CHENG | 1 | 54.1% | +64.1% |
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.3% | +49.2% |
| DAUNER, JOSEPH G | 1 | 56.9% | +35.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18467633 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SHAMEEM, GOLAM M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010970 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | DAUNER, JOSEPH G | 9d overdue |
| 18039473 | MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES | LU, CHENG | 46d |
| 18182203 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | DUFFY, PATRICIA ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17762867 | Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers | ALSOMAIRY, SARAH ABDOALATIF | 72d overdue |
| 18017905 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | ALSOMAIRY, SARAH ABDOALATIF | 30d overdue |
| 18010970 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | DAUNER, JOSEPH G | 9d overdue |
| 18039473 | MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES | LU, CHENG | 46d |
| 18682886 | METHODS FOR TREATING NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | PETRASH, HILARY ANN | — |
| 18018504 | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | ALLEN, MARIANNE P | — |
| 18467633 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SHAMEEM, GOLAM M | — |
| 18449591 | METHODS OF REDUCING SIDE EFFECTS OF ANTI-CD30 ANTIBODY DRUG CONJUGATE THERAPY | BENAVIDES, JENNIFER ANN | — |
| Art Unit | Apps |
|---|---|
| 1646 | 4 |
| 1642 | 3 |
| 1647 | 1 |
| 1674 | 1 |
| 1675 | 1 |
| 1645 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682886 | METHODS FOR TREATING NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | PETRASH, HILARY ANN | — | §103§112DP | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18018504 | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | ALLEN, MARIANNE P | 1647 | §102§103§112DP | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18467633 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SHAMEEM, GOLAM M | 1674 | DP | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18449591 | METHODS OF REDUCING SIDE EFFECTS OF ANTI-CD30 ANTIBODY DRUG CONJUGATE THERAPY | BENAVIDES, JENNIFER ANN | 1675 | §103 | Non-Final OA | — | Pending | Aug 14, 2023 |
| 18222313 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | PUTTLITZ, KARL J | 1646 | §102 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18039473 | MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES | LU, CHENG | 1642 | §103§112Other | Non-Final OA | 46d | Pending | May 30, 2023 |
| 18182203 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | DUFFY, PATRICIA ANN | 1645 | §102§112 | Non-Final OA | — | Pending | Mar 10, 2023 |
| 18025349 | METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | STONEBRAKER, ALYSSA RAE | 1642 | §102§103DP | Non-Final OA | — | Pending | Mar 08, 2023 |
| 18017905 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103 | Final Rejection | 30d overdue | Pending | Jan 25, 2023 |
| 18010970 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | DAUNER, JOSEPH G | 1682 | §103§112 | Final Rejection | 9d overdue | Pending | Dec 16, 2022 |
| 17926206 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND AN OXALIPLATIN-BASED CHEMOTHERAPY | XIAO, YAN | 1642 | §103 | Final Rejection | 43d overdue | Pending | Nov 18, 2022 |
| 17762867 | Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers | ALSOMAIRY, SARAH ABDOALATIF | 1646 | DP | Final Rejection | 72d overdue | Pending | Mar 23, 2022 |
| 17634026 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | PUTTLITZ, KARL J | 1646 | §103DP | Non-Final OA | — | Pending | Feb 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial